JAZZ - Jazz Pharmaceuticals PLC

https://www.jazzpharma.com

Momentum: Bearish

Recent News

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Zacks Commentary • 3 weeks, 4 days ago • score: 0.33

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.

52W High

$148.06

52W Low

$95.49

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.24

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

6.51

EV/EBITDA (<8 favorable)

31.21

EV/Revenue (<3 favorable)

2.84

P/S (TTM) (<3 favorable)

1.92

P/B (<3 favorable)

2.12

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

3.11%

Institutions (25–75% balanced)

105.77%

Shares Outstanding

60,659,000

Float

58,655,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,086,695,000

Gross Profit (TTM)

3,765,300,000

EPS (TTM)

-6.98

Profit Margin (>10% good)

-0.10%

Operating Margin (TTM) (higher better)

0.21%

ROE (TTM) (>15% strong)

-0.11%

EPS YoY (Quarterly) (>10% good)

1.19

Revenue YoY (Quarterly) (>8% good)

0.02

Momentum

Bearish momentum

Value

3.5965

4.0506

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025